

## Instructions for Authors 2017

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

***Nomenclature and Abbreviations.*** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

***Clinical Trials.*** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

***Ethical Policies and Standards.*** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

***Submission of Manuscripts.*** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

***Galley Proofs.*** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2017** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.



- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online only and open access (effective January 2017) with Stanford University HighWire Press

ISSN (online): 1791-7549

### General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

### Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

### Selection of Recent Articles

Effectiveness of Analogues of the GS-Nitroxide, JP4-039, as Total Body Radiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. KRAINZ, X. ZHANG, P. WIPF, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Wound Healing is Delayed in the ZDSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (*St. Paul, MN; Indianapolis, IN, USA*)

Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H.SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (*Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA*)

Effective Mediastinal Lymphadenectomy for Esophageal Cancer Using Slender Tracheal Forceps in Prone Position Thoracoscopic Esophagectomy. M. NAKAJIMA, M. TAKAHASHI, Y. DOMEKI, H. SATOMURA, H. MUROI, M. KIKUCHI, H. OGATA, S. YAMAGUCHI, K. SASAKI, M. SAKAI, M. SOHDA, T. MIYAZAKI, H. KUWANO, H. KATO (*Mibu; Maebashi, Japan*)

A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (*California; Pittsburgh, PA; Newark, NJ, USA*)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (*Copenhagen, Denmark*)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (*Saitama, Japan*)

Polymorphism in Murine mtATP8 Gene Correlates with Decreased Reactive Oxygen Species in Aging Hematopoietic Cells. C. ROOLF, C. KRETZSCHMAR, K. TIMMER, A. SEKORA, G. KNÜBEL, H.M. ESCOBAR, G. FUELLEN, S.M. IBRAHIM, M. TIEDGE, S. BALTRUSCH, S. MÜLLER, R. KÖHLING, C. JUNGHANSS (*Rostock, Germany*)

Induction of TGF- $\beta$  by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (*Nara, Japan*)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C.C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (*Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC*)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (*Odense; Copenhagen, Denmark*)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLAND (*Tromsø; Bodø, Norway*)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (*Jackson, MS, USA*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# CANCER GENOMICS & PROTEOMICS

[www.cgp.iarjournals.org](http://www.cgp.iarjournals.org)

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (*Spokane, WA; Duarte, CA, USA*)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (*Basel, Switzerland*)

EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6 Expressing MDA-MB-231 Cells. C. JOHNSON, B. SEGOVIA, R.P. KANDPAL (*Pomona, CA, USA*)

Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (*Los Angeles, CA; Boston, MA, USA; London, UK*)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (*Basel, Switzerland*)

Association of BIM Deletion Polymorphism and BIM- $\gamma$  RNA Expression in NSCLC with EGFR Mutation. K. ISOBE, A. KAKIMOTO, T. MIKAMI, K. KABURAKI, H. KOBAYASHI, T. YOSHIZAWA, T. MAKINO, H. OTSUKA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, N. TOCHIGI, A. IYODA, S. HOMMA (*Tokyo, Japan*)

High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (*Vitis vinifera*) in HeLa cells. E.A. MAZZIO, K.F.A. SOLIMAN (*Tallahassee, FL, USA*)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (*Austin, TX; Cambridge, MA, USA*)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (*Uppsala; Halmstad, Sweden*)

Characterization of Heparan Sulfate Proteoglycan-positive Recycling Endosomes Isolated from Glioma Cells. K.A. PODYMA-INOUE, T. MORIWAKI, A.R. RAJAPAKSHE, K. TERASAWA, M. HARA-YOKOYAMA (*Tokyo, Japan*)

Overexpression of HPV16 E6\* Alters  $\beta$ -Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (*Loma Linda, CA, USA*)

# Subscription Order Form 2017

- Please enter a Subscription to ANTICANCER RESEARCH Volume 37 (2017).  
Annual subscription rates (2017): Institutional, US\$ 1898.00 online, US\$ 2277.00 online & print; Personal, US\$ 897.00 online; US\$ 1277.00 online & print; Prices include rapid delivery and insurance.  
2017 online subscriptions include free online access to vol. 24 (2004) - 36 (2016).
- Please send me the following previous volumes (1-36) at 50% discount on the above rates:
- Please invoice.
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....

.....

Tel: .....

Fax: ..... e-mail: .....

Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

## Special 2017 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2017 on a basis of priority and availability. Effective from January to December 2017).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 35 years.

- 1981-2016
- 36 volumes
- over 124,000 pages
- over 18,500 original articles
- 928 reviews
- over 85,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:

ANTICANCER RESEARCH, International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

### Special Subscription Order Form 2017

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2017 (Volume 37) at the special Author's rate of US\$ 465.00 (print or online).
- Please send me previous Volume No(s) ..... at US\$ 224.00 (print) per volume.
- Please send me an invoice.  
Prices include rapid delivery and insurance.

Name and address: .....

.....

Tel-Fax: .....

e-mail: .....

Date and signature: .....

Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab. Y. TANIGUCHI, A. TAMIYA, S.-I. ISA, K. NAKAHAMA, K. OKISHIO, T. SHIROYAMA, H. SUZUKI, T. INOUE, M. TAMIYA, T. HIRASHIMA, F. IMAMURA, S. ATAGI ( <i>Sakai; Habikino; Osaka, Japan</i> ) .....	5857
Perioperative Red Blood Cell Transfusion Is Associated with Poor Long-term Survival in Pancreatic Adenocarcinoma. T. ABE, H. AMANO, K. HANADA, T. MINAMI, S. YONEHARA, M. HATTORI, T. KOBAYASHI, T. FUKUDA, M. NAKAHARA, H. OHDAN, T. NORIYUKI ( <i>Onomichi; Hiroshima, Japan</i> ) ....	5863
Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients. F. SHOJI, N. YAMASHITA, Y. INOUE, Y. KOZUMA, G. TOYOKAWA, F. HIRAI, K. ITO, T. TAGAWA, T. OKAMOTO, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	5871
miR-223 and Stathmin-1 Expression in Non-tumor Liver Tissue of Patients with Hepatocellular Carcinoma. S. IMURA, S. YAMADA, Y. SAITO, S. IWAHASHI, Y. ARAKAWA, T. IKEMOTO, Y. MORINE, T. UTSUNOMIYA, M. SHIMADA ( <i>Tokushima; Oita, Japan</i> ).....	5877
The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter. K. NAKAHAMA, S.-I. ISA, A. TAMIYA, Y. TANIGUCHI, T. SHIROYAMA, H. SUZUKI, T. INOUE, M. TAMIYA, T. HIRASHIMA, F. IMAMURA, S. ATAGI ( <i>Sakai; Habikino; Osaka, Japan</i> ) .....	5885
Gastric Spindle Cell Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: Unique Morphology and Diagnostic Pitfall. A.A. LEE, N. PODDAR, M.B. HAMMAMI, J. VEERAPONG, D. CAO, J.-P. LAI ( <i>St. Louis, MO; Gainesville, FL, USA</i> ) .....	5893
Differential Prognostic Value of Metabolic Heterogeneity of Primary Tumor and Metastatic Lymph Nodes in Patients with Pharyngeal Cancer. J.Y. JANG, K.J. PAK, K.-I. YI, Y.K. KI, W.T. KIM, H. KIM, Y.J. CHOI, S.J. KIM, I.J. KIM, S.-G. WANG, Y.M. SEOL ( <i>Busan; Yangsan, Republic of Korea</i> ) .....	5899
Book Reviews .....	5907
Announcements .....	5910

Transanal Assisted Resection with Closure of Anal Canal for Lower Rectal Diseases. H. KAWAHARA, T. AKIBA, K. YANAGA ( <i>Chiba; Tokyo, Japan</i> ) .....	5767
Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs. A. TAKEUCHI, T. OGURI, K. SONE, K. ITO, Y. KITAMURA, Y. INOUE, T. ASANO, S. FUKUDA, Y. KANEMITSU, O. TAKAKUWA, H. OHKUBO, M. TAKEMURA, K. MAENO, Y. ITO, A. NIIMI ( <i>Nagoya, Japan</i> ) .....	5771
Association Between Interleukin-10 Receptors and the CD45-Immunophenotype of Central Nervous System Tumors: A Preliminary Study. U. ZADKA, P. KRAM, J. KOSCINSKI, R. JANKOWSKI, M. KACZMAREK, K. PIATEK, M. KULUS, A. GOMULKIEWICZ, A. PIOTROWSKA, P. DZIEGIEL ( <i>Wroclaw; Lublin; Poznan, Poland</i> ) .....	5777
Microsatellite Status of Primary Colorectal Cancer Predicts the Incidence of Postoperative Colorectal Neoplasms. A. TAKIYAMA, T. TANAKA, Y. YAMAMOTO, K. HATA, S. ISHIHARA, H. NOZAWA, K. KAWAI, T. KIYOMATSU, T. NISHIKAWA, K. OTANI, K. SASAKI, T. WATANABE ( <i>Tokyo, Japan</i> ).....	5785
The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis. Y. MATSUMOTO, S. OHARA, R. FURUKAWA, K. USUI ( <i>Tokyo, Japan</i> ) .....	5791
Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery. S. IDE, Y. TOIYAMA, Y. OKUGAWA, S. OKI, H. YASUDA, H. FUJIKAWA, S. YOSHIYAMA, J. HIRO, M. KOBAYASHI, M. OHI, T. ARAKI, M. KUSUNOKI ( <i>Tsu, Japan</i> ).....	5797
Immunohistochemical Comparison of Malignancy Between Radial Invasion and Mucosal Extension in Hilar Cholangiocarcinoma. K. YOSHIDA, R. MATSUYAMA, R. MORI, T. KUMAMOTO, K. MATSUO, K. TAKEDA, M. SUGITA, Y. FUJII, K. TANAKA, H. SHIMADA, I. ENDO ( <i>Yokohama; Miyazaki, Japan</i> ) ....	5805
Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial. M.K. KARMAKAR, W. SAMY, A. LEE, J.W. LI, W.C. CHAN, P.P. CHEN, B.C.H. TSUI ( <i>Shatin; New Territories, Hong Kong, PR China; Stanford, CA, USA</i> ) .....	5813
Hypofractionated Postoperative IMRT in Prostate Carcinoma: A Phase I/II Study. G. MACCHIA, G. SIEPE, I. CAPOCACCIA, N.P. NGUYEN, R. SCHIAVINA, S. CAMELLI, S. GUERRI, A. ARCELLI, M. BUWENGE, M. NTRETA, S. CILLA, V. VALENTINI, F. DEODATO, A.G. MORGANTI ( <i>Campobasso; Bologna; Rome, Italy; Washington, DC, USA</i> ).....	5821
Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy. D. SHIMIZU, H. YAMAZAKI, T. NISHIMURA, N. AIBE, H. OKABE ( <i>Kyoto; Uji, Japan</i> ).....	5829
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer. S. MOTOYAMA, Y. SATO, T. SASAKI, A. WAKITA, Y. KAWAKITA, J. LIU, Y. NAGAKI, H. SAITO, K. IMAI, H. KONNO, K.T. MIZUSAWA, Y. MINAMIYA ( <i>Akita, Japan</i> ).....	5837
Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. K. KISHIMOTO, R. KOBAYASHI, D. HORI, H. SANO, D. SUZUKI, K. KOBAYASHI ( <i>Sapporo, Japan</i> ) .....	5845
A Proposal for Progression-free Survival Assessment in Patients with Early Progressive Cancer. T. TANASE, C. HAMADA, T. YOSHINO, A. OHTSU ( <i>Tokyo; Kashiwa, Japan</i> ).....	5851



Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization. N. RATHMANN, K. KARA, J. BUDJAN, T. HENZLER, A. SMAKIC, S.O. SCHOENBERG, S.J. DIEHL ( <i>Mannheim, Germany</i> ).....	5681
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review. Y. FUJIMOTO, Y. NAKASHIMA, S. SASAKI, T. JOGO, K. HIROSE, K. EDAHIRO, S. KOREHISA, D. TANIGUCHI, K. KUDOU, Y. NAKAJI, R. NAKANISHI, K. ANDO, H. SAEKI, E. OKI, M. FUJIWARA, Y. ODA, Y. MAEHARA ( <i>Fukuoka, Japan</i> ).....	5687
Accurate Estimation of Functional Liver Volume Using Gd-EOB-DTPA MRI Compared to MDCT/ <sup>99m</sup> Tc-SPECT Fusion Imaging. Y. MORINE, C. ENKHBOLD, S. IMURA, T. IKEMOTO, S. IWAHASHI, Y. SAITO, S. YAMADA, T. UTSUNOMIYA, M. SHIMADA ( <i>Tokushima, Japan</i> ).....	5693
CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection. Y. MORINE, S. IMURA, T. IKEMOTO, S. IWAHASHI, Y. SAITO, M. SHIMADA ( <i>Tokushima, Japan</i> ).....	5701
Debulking Surgery for Clear Cell Carcinoma of the Ovary – A Case Report and Literature Review. N. BACALBASA, I. BALESCU, A. FILIPESCU ( <i>Bucharest, Romania</i> ).....	5707
Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. N. HARATAKE, G. TOYOKAWA, T. TAGAWA, Y. KOZUMA, T. MATSUBARA, S. TAKAMORI, T. AKAMINE, Y. YAMADA, Y. ODA, Y. MAEHARA ( <i>Fukuoka, Japan</i> ).....	5713
Uveal Melanoma: <i>GNAQ</i> and <i>GNA11</i> Mutations in a Greek Population. F. PSINAKIS, A. KATSELI, C. KOUTSANDREA, K. FRANGIA, L. FLORENTIN, D. APOSTOLOPOULOU, K. DIMAKOPOULOU, D. PAPAKONSTANTINOY, E. GEORGOPOULOU, D. BROUZAS ( <i>Athens, Greece</i> ).....	5719
The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. M.K. ANGELOPOULOU, E. MOSA, G.A. PANGALIS, P. RONDOGIANNI, S. CHATZIIIOANNOU, V. PRASSOPOULOS, M. MOSCHOGIANNI, P. TSIRKINIDIS, J.V. ASIMAKOPOULOS, I. KONSTANTINOY, G. TSOUROUFLIS, S. SACHANAS, X. YIAKOUMIS, G. BOUTSIKAS, M. ARAPAKI, G. GAINARU, M.-C. KYRTSONIS, M.P. SIAKANTARIS, I. DATSERIS, P. PANAYIOTIDIS, K. KONSTANTOPOULOS, T.P. VASSILAKOPOULOS ( <i>Athens, Greece</i> ).....	5727
Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. A. SAXENA, S.J. VALLE, W. LIAUW, D.L. MORRIS ( <i>Kogarah, NSW, Australia</i> ).....	5737
Cuff-less J Pouch Anal Stapling Anastomosis for Ulcerative Colitis. H. KAWAHARA, T. AKIBA, K. YANAGA ( <i>Chiba; Tokyo, Japan</i> ).....	5743
ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. D. D’ANDREA, M. MOSCHINI, F. SORIA, K.M. GUST, A. BRIGANTI, P.I. KARAKIEWICZ, M. ROUPRET, S.F. SHARIAT ( <i>Vienna, Austria; Milan; Turin, Italy; Quebec, QC, Canada; Paris, France; Dallas, TX; New York, NY, USA</i> ).....	5747
Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy. K. IWAMA, H. YAMAZAKI, D. SHIMIZU, G. SUZUKI, S. NAKAMURA, N. SASAKI, T. TAKENEKA, H. OKABE, T. NISHIKAWA, K. YOSHIDA ( <i>Uji; Kamigyo; Takatsuki, Japan</i> ).....	5755
The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients. R. AIZAWA, M. SAKAMOTO, N. ORITO, M. KONO, M. OGURA, Y. NEGORO, T. SAGOH, K. TSUKAHARA, K. KOMATSU, M. NOGUUCHI ( <i>Fukui; Kyoto; Kishiwada; Tenri, Japan</i> ).....	5761

Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base. Q.D. CHU, M. ZHOU, K.L. MEDEIROS, P. PEDDI, X.C. WU ( <i>Louisiana; Shreveport; New Orleans, LA, USA</i> ).....	5585
Reconstruction After Distal Gastrectomy for Gastric Cancer: Billroth 2 or Roux-En-Y Procedure? E. VIRGILIO, G. BALDUCCI, P. MERCANTINI, M. FERRI, T. BOCCHETTI, S. CATERINO, P.F. SALVI, V. ZIPARO, M. CAVALLINI ( <i>Rome, Italy</i> ).....	5595
Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics. W. HAQUE, V. VERMA, E.B. BUTLER, B.S. TEH ( <i>The Woodlands; Houston, TX; Omaha, NE, USA</i> ).....	5603
The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study. K. GUNGORDUK, O. ASICIOGLU, E.I. BRAICU, J. ALMUHEIMID, S.G. GOKULU, N. CETINKAYA, T. GUNGOR, G. PAKAY, E.U. TELLI, Z.F. CUYLAN, T. TOPTAS, A. BILGI, R. OZYURT, E. AGACAYAK, A. OZDEMIR, N. YILDIRIM, S. TASKIN, T. OGE, O. EROL, L. AKMAN, A. TURAN, M.S. ICEN, T. SENOL, O.I. OVALI, B. YUCESOY, O. GUNGORDUK, O. TEMIZKAN, M. SANCI, T. SIMSEK, M.M. MEYDANLI, M. HARMA, L. YASAR, A.D. UYSAL, A. KARATEKE, F. ORTAC, S.S. OZALP, J. SEHOULI, M.Z. MUALLEM ( <i>Mugla; Istanbul; Izmir; Trabzon; Ankara; Eskisehir; Antalya; Diyarbakir; Zonguldak, Turkey; Berlin, Germany</i> ).....	5609
Feasibility of Transanal Local Excision Following Chemoradiation for Lower Rectal Cancer. T. TOKUNAGA, M. NISHI, J. HIGASHIJIMA, K. YOSHIKAWA, H. KASHIHARA, C. TAKASU, D. ISHIKAWA, Y. BANDO, M. SHIMADA ( <i>Kuramoto, Japan</i> ).....	5617
Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. S. KASHIWAGI, Y. ASANO, W. GOTO, K. TAKADA, K. TAKAHASHI, T. HATANO, T. TAKASHIMA, S. TOMITA, H. MOTOMURA, M. OHSAWA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ).....	5623
Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer. H. OBATA, M. SHIOTA, N. AKITAKE, A. TAKEUCHI, E. KASHIWAGI, T. DEJIMA, K. KIYOSHIMA, J. INOKUCHI, K. TATSUGAMI, M. ETO ( <i>Fukuoka, Japan</i> ).....	5631
Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma. Y. HAMAI, J. HIHARA, M. EMI, T. FURUKAWA, Y. IBUKI, I. YAMAKITA, T. KUROKAWA, M. OKADA ( <i>Hiroshima, Japan</i> ).....	5639
Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer. K. HE, X. WANG, X. GUAN, Q. YU, Q. MA, Z. LIU, Z. YU ( <i>Jinan; Rizhao, PR China; Lexington, KY, USA</i> ).....	5647
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. A. HAYANO, Y. KOMOHARA, Y. TAKASHIMA, H. TAKEYA, J. HOMMA, J. FUKAI, Y. IWADATE, K. KAJIWARA, S. ISHIZAWA, H. HONDOH, R. YAMANAKA ( <i>Kyoto; Kumamoto; Toyama; Wakayama; Chiba; Ube, Japan</i> ).....	5655
Compensation Claims for Sub-standard Care of Patients with Gastroentero-pancreatic Neuroendocrine Tumors: A Nationwide Descriptive Study of Cases Between 2005-2016 in Norway. K.F. DESSERUD, I. BUKHOLM, J.A. SOREIDE ( <i>Stavanger; Oslo; Bergen, Norway</i> ).....	5667
Potential Pitfalls of a Fiducial Marker-matching Technique in Carbon-ion Radiotherapy for Lung Cancer. S. SHIBA, J.-I. SAITOH, D. IRIE, K. SHIRAI, T. ABE, Y. KUBOTA, M. SAKAI, R. OKADA, T. OHNO, T. NAKANO ( <i>Gunma, Japan</i> ).....	5673

Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity. C. BOBIN-DUBIGEON, A. CHAUVIN, V. BRILLAUD-MEFLAH, F. BOIFFARD, M.-P. JOALLAND, J.-M. BARD (Saint-Herblain; Nantes, France).....	5495
Photodynamic Therapy Using Indolines-Fused-Triazoles Induces Mitochondrial Apoptosis in Human Non-Melanoma BCC Cells. W.-P. HU, K.-K. KUO, G.C. SENADI, L.-S. CHANG, J.-J. WANG (Kaohsiung, Taiwan, ROC) .....	5499
Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells <i>In Vitro</i> . D.-H. PHAM, J.-S. KIM, S.-K. KIM, D.-J. SHIN, N.-T.-T. UONG, H. HYUN, M.S. YOON, S.J. KANG, Y.J. RYU, J.S. CHO, J.H. YOON, J.S. LEE, D. CHO, S.-H. LEE, M.H. PARK (Gwangju; Yesan; Jeollanam-do; Seoul, Republic of Korea) .....	5507
Down-regulation of Toll-like Receptor TLR4 Is Associated with HPV DNA Integration in Penile Carcinoma. M. DAMASDI, K. KOVACS, N. FARKAS, F. JAKAB, G. KOVACS (Pecs, Hungary; Heidelberg, Germany) .....	5515
Deregulation of PTEN Expression in Laryngeal Squamous Cell Carcinoma Based on Tissue Microarray Digital Analysis. N.S. MASTRONIKOLIS, E. TSIAMBAS, T.A. PAPADAS, A. KARAMERIS, V. RAGOS, D. PESCHOS, S.N. MASTRONIKOLIS, A.T. PAPADAS, C. LIATSOS, I.E. ARMATA, P.P. FOTIADES (Patras; Athens; Ioannina; Heraklion, Greece; Madison, WI, USA; Nicosia, Cyprus; Leicester, UK).....	5521
Down-regulation of Inositol Polyphosphate 4-Phosphatase Type II Expression in Colorectal Carcinoma. J.-Y. SUNG, K. NA, H.-S. KIM (Seoul, Republic of Korea) .....	5525
<i>Clinical Studies</i>	
Impact of Nab–Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. N. DADI, M. STANLEY, S. SHAHDA, B.H. O’NEIL, A. SEHDEV (Indianapolis, IN, USA) .....	5533
Peripheral Tr1 and Foxp3+ Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers. T. IKEMOTO, M. SHIMADA, D. ISHIKAWA, Y. KAWASHITA, H. TERAOKU, M. YOSHIKAWA, S. YAMADA, Y. SAITO, Y. MORINE, S. IMURA (Tokushima, Japan) .....	5541
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients – AGMT_GASTRIC-3. E. WÖLL, J. THALER, F. KEIL, B. GRUENBERGER, M. HEJNA, W. EISTERER, M.A. FRIDRIK, H. ULMER, V. TROMMET, F. HUEMER, L. WEISS, R. GREIL (Zams; Wels; Vienna; Innsbruck; Linz; Salzburg, Austria) .....	5553
Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer. K. IZUMI, K. SHIGEHARA, T. NOHARA, K. NARIMOTO, Y. KADONO, A. MIZOKAMI (Kanazawa, Japan) .....	5559
Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab. K. SUDO, K. SATO, S. SAKAMOTO, Y. HASEGAWA, M. ASANO, Y. OKUDA, M. TAKEDA, M. SANO, H. WATANABE, T. SHIOYA, H. ITO (Akita, Japan) .....	5565
Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases. M. YASUKAWA, T. KAWAGUCHI, N. KAWAI, T. TOJO, S. TANIGUCHI (Kashihara, Japan) .....	5573
Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers. S. SHIBA, N. OKONOJI, S. KATO, M. WAKATSUKI, D. KOBAYASHI, H. KIYOHARA, T. OHNO, K. KARASAWA, T. NAKANO, T. KAMADA (Chiba; Maebashi; Hidaka; Shimotsuke; Kumagaya; Tokyo, Japan) .....	5577

Do Dental X-Rays Induce Genotoxicity and Cytotoxicity in Oral Mucosa Cells? A Critical Review. F. ANGELIERI, V. QUISPE YUJRA, C.T.F. OSHIMA, D.A. RIBEIRO ( <i>Sao Paulo, Brazil</i> ).....	5383
The Role of Toll Like Receptors (TLRs) in Oral Carcinogenesis. L. PELLEGRINI PISANI, D. ESTADELLA, D.A. RIBEIRO ( <i>Santos, SP, Brazil</i> ) .....	5389
Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature. S. GIGLI, M.I. AMABILE, F. DI PASTENA, A. DE LUCA, C. GULIA, L. MANGANARO, M. MONTI, L. BALLELIO ( <i>Rome, Italy</i> ) .....	5395
<i>Experimental Studies</i>	
Predictive Value of Sphingosine Kinase 1 Expression in Papillary Thyroid Carcinoma. S.-I. DO, H.-S. KIM, K. KIM, H. LEE, I.-G. DO, D.-H. KIM, S.W. CHAE, J.H. SOHN ( <i>Seoul, Republic of Korea</i> ) .....	5399
Comparison of Cold Atmospheric Plasma Devices' Efficacy on Osteosarcoma and Fibroblastic <i>In Vitro</i> Cell Models. D. GÜMBEL, B. SUCHY, L. WIEN, N. GELBRICH, M. NAPP, A. KRAMER, A. EKKERNKAMP, G. DAESCHLEIN, M.B. STOPE ( <i>Greifswald; Berlin, Germany</i> ).....	5407
Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells. K.-J. YANG, L. PIAO, S. SHIN, S.-Y. SHIN, Y. LI, H. LEE, Q. TRAN, J. PARK, S. HONG, D.P. BRAZIL, B.A. HEMMINGS, S.-H. KIM, J. PARK ( <i>Daejeon; Incheon, Republic of Korea; Yanji; Xi'an, PR China; Belfast, Northern Ireland, UK; Basel, Switzerland</i> ) .....	5415
Suppression of Oral Carcinoma Oncogenic Activity by microRNA-203 via Down-regulation of <i>SEMA6A</i> . H.-S. LIM, C.S. KIM, J.-S. KIM, S.-K. YU, D.-S. GO, S.A. LEE, S.M. MOON, H.S. CHUN, S.G. KIM, D.K. KIM ( <i>Gwangju, Republic of Korea</i> ).....	5425
Expression of Epithelial–Mesenchymal Transition Regulating Transcription Factors in Head and Neck Squamous Cell Carcinomas. J. GÖPPEL, N. MÖCKELMANN, A. MÜNSCHER, G. SAUTER, U. SCHUMACHER ( <i>Hamburg, Germany</i> ).....	5435
Clinicopathological Characteristics of Ovarian Sclerosing Stromal Tumor with an Emphasis on TFE3 Overexpression. C.K. PARK, H.-S. KIM ( <i>Seoul; Seongnam, Republic of Korea</i> ).....	5441
Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: “Oncogenic” Versus “Onco-Suppressive” Reactive Oxygen Species. R. BAKALOVA, Z. ZHELEV, S. SHIBATA, B. NIKOLOVA, I. AOKI, T. HIGASHI ( <i>Chiba, Japan; Sofia; Stara Zagora, Bulgaria</i> ) .....	5449
<i>GTF2I</i> Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. G. TARRINI, E. CIABATTI, S. PACINI, S. GALIMBERTI, I. PETRINI ( <i>Pisa, Italy</i> ) .....	5459
Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil. M. IKEMURA, T. HASHIDA ( <i>Kobe, Japan</i> ) .....	5463
Effects of S1P1 and S1P3 in ER <sup>+</sup> and ER <sup>-</sup> Breast Cancer Cells. I.U. CALIS, D.T. COSAN, F. MUTLU ( <i>Eskisehir, Turkey</i> ).....	5469
Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin. S. KISHIMOTO, M. YASUDA, S. FUKUSHIMA ( <i>Kobe, Japan</i> ) .....	5477
Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma. J. GRZEGRZOLKA, P. WOJTYRA, M. BIALA, A. PIOTROWSKA, A. GOMULKIEWICZ, J. RYS, M. PODHORSKA-OKOLOW, P. DZIEGIEL ( <i>Wroclaw; Cracow, Poland</i> ).....	5485